LEGN
Legend Biotech Corp
NASDAQ · Healthcare · Biotechnology · US
$18.65
+0.92%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$18.55
From 52W high−48.59%
Volume1.89M
Market cap$3.63B
P/E (TTM)—
P/S (TTM)2.9x
Div yield—
Key dataOct 19, 2026
Open
$18.55
From 52W high
−48.59%
Volume
1.89M
Market cap
$3.63B
ValuationView details →
P/E (Fwd)
31.9x
EV/EBITDA
1430.3x
P/E (TTM)
—
RSI (14)
44.6
MomentumView details →
1D Return
+0.92%
YTD Return
−16.24%
SummaryUpdated Jun 1, 2026
Legend Biotech Corporation (NASDAQ:LEGN) is a clinical-stage biopharmaceutical company founded in 2014 and headquartered in Somerset, New Jersey. The company is a subsidiary of Genscript Biotech Corporation and went public in June 2020. Legend Biotech specializes in developing innovative cell therapies, particularly CAR-T (Chimeric Antigen Receptor T-cell) therapies for treating various cancers and other diseases. The company has achieved significant commercial success with its lead product CARVYKTI, which has become a leading treatment for multiple myeloma, and continues to expand its pipeline of cell therapy candidates targeting both blood cancers and solid tumors.
Similar companies
Latest newsMore news →
Legend Biotech Corp announced that CARVYKTI had net trade sales of approximately $710 million for the quarter ended September 30, 2026, based on information provided by JOHNSON & JOHNSON and not independently verified by Legend Biotech Corp or GenScript.6d agoLegend Biotech presented five-year data for CARVYKTI showing that half of patients with relapsed or refractory multiple myeloma remained progression-free and alive five years after a single infusion, with a five-year overall survival rate of 69.2%.25d ago